Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-119249
Filing Date
2024-10-31
Accepted
2024-10-31 07:45:53
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kymr-20240930.htm   iXBRL 10-Q 2601030
2 EX-10.1 kymr-ex10_1.htm EX-10.1 58066
3 EX-10.2 kymr-ex10_2.htm EX-10.2 307597
4 EX-31.1 kymr-ex31_1.htm EX-31.1 16774
5 EX-31.2 kymr-ex31_2.htm EX-31.2 16664
6 EX-32.1 kymr-ex32_1.htm EX-32.1 9251
7 EX-32.2 kymr-ex32_2.htm EX-32.2 9144
  Complete submission text file 0000950170-24-119249.txt   10307835

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kymr-20240930.xsd EX-101.SCH 1402161
76 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20240930_htm.xml XML 1743286
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 241412479
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)